

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 078 637 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

**28.02.2001 Bulletin 2001/09**

(51) Int Cl.7: **A61K 45/06**

(21) Application number: **00307254.3**

(22) Date of filing: **23.08.2000**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**

Designated Extension States:

**AL LT LV MK RO SI**

• **Harrigan, Edmund Patrick**

**Groton, Connecticut 06340 (US)**

• **O'Neill, Brian Thomas**

**Groton, Connecticut 06340 (US)**

• **Sands, Steven Bradley**

**Groton, Connecticut 06340 (US)**

(30) Priority: **27.08.1999 US 151089 P**

(71) Applicant: **Pfizer Products Inc.**

**Groton, Connecticut 06340 (US)**

(74) Representative:

**Simpson, Alison Elizabeth Fraser et al**

**Urquhart-Dykes & Lord,**

**30 Welbeck Street**

**London W1G 8ER (GB)**

(72) Inventors:

• **Coe, Jotham Wadsworth**

**Groton, Connecticut 06340 (US)**

(54) **Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug**

(57) Pharmaceutical compositions are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse. The pharma-

ceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-depressant or anxiolytic agent and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

P 1 078 637 A2

**Description**

Background of the Invention

[0001] The present invention relates to pharmaceutical compositions for the treatment of nicotine dependence or addiction in a mammal (e.g. human) comprising a nicotine receptor partial agonist (NRPA) and an anti-depressant or anxiolytic agent. The term NRPA refers to all chemical compounds which bind at neuronal nicotinic acetylcholine specific receptor sites in mammalian tissue and elicit a partial agonist response. A partial agonist response is defined here to mean a partial, or incomplete functional effect in a given functional assay. Additionally, a partial agonist will also exhibit some degree of antagonist activity by its ability to block the action of a full agonist (Feldman, R.S., Meyer, J.S. & Quenzer, L.F. Principles of Neuropsychopharmacology, 1997; Sinauer Assoc. Inc.). The present invention may be used to treat mammals (e.g. humans) for tobacco dependence or addiction and nicotine dependence or addiction; to palliate the effects of nicotine withdrawal and to enhance the outcomes of other smoking cessation therapies.

[0002] The invention also relates to aryl fused azapolycyclic compounds that bind to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function and are referred to in WO 9818798-A1, WO 9935131-A1 and WO 9955680-A1. The foregoing applications are owned in common with the present application and are incorporated herein by reference in their entireties.

[0003] The NRPA compounds that bind to neuronal nicotinic receptor sites can be used in combination with an anti-depressant such as for example, a tricyclic anti-depressant (e.g. amitriptyline, imipramine), a serotonin reuptake inhibitor anti-depressant (SRI) (e.g. sertraline, paroxetine, or fluoxetine), an atypical anti-depressant (bupropion, nefazodone), or a monoamine oxidase inhibitor (e.g., phenelzine, tranylcypromine) in order to treat the depression associated with addiction such as to nicotine or tobacco, alcohol dependence, cocaine addiction or tobacco or nicotine dependence independently of other psychiatric illness. The compounds that bind to neuronal nicotinic receptor sites can be used in combination with anxiolytic agents, such as for example, a benzodiazepine (e.g. diazepam, alprazolam, chlordiazepoxide) or non-benzodiazepine anxiolytics (e.g. buspirone, hydroxyzine, doxepin) in order to treat the anxiety associated with addiction such as to nicotine or tobacco, alcohol dependence, cocaine addiction or tobacco or nicotine dependence independently of other psychiatric illness.

[0004] Tobacco dependence represents the most important preventable cause of illness and death in our society, responsible for more than 400,000 deaths each year. Half of all smokers will die of diseases directly related to tobacco use, and many smokers will suffer sig-

nificant morbidity.

[0005] People smoke because of the reinforcing effects of nicotine. Nicotine is a powerful psychoactive agent that activates the same brain pathways as cocaine and other psychostimulants, producing agent-associated tolerance and withdrawal effects.

[0006] Nicotine replacement therapies (NRTs) have been used for smoking cessation. These are available in the form of gum, the transdermal patch, and nasal inhaler. The gum Nicorette® (nicotine polacrilex) delivers nicotine through buccal absorption following chewing. There are also non-nicotine pharmacologic therapies for treating nicotine addiction.

Summary of Invention

[0007] The invention provides a pharmaceutical composition for treating nicotine dependence or addiction, tobacco dependence or addiction, reducing nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse. The therapeutically effective pharmaceutical combination is comprised of a nicotine receptor partial agonist and an anti-depressant or anxiolytic agent and a pharmaceutically acceptable carrier.

[0008] In a more specific embodiment of the invention, the anti-depressant is selected from a tricyclic anti-depressant, a serotonin reuptake inhibitor anti-depressant (SRI), an atypical anti-depressant or a monoamine oxidase inhibitor, their pharmaceutically active salts and their optical isomers. In another more specific embodiment of the invention, the anti-depressant is selected from amitriptyline, imipramine, sertraline, paroxetine, fluoxetine, bupropion, nefazodone, phenelzine, tranylcypromine, moclobemide, venlafaxine or a pharmaceutically acceptable salt or their optical isomers thereof. A preferred antidepressant is bupropion hydrochloride or one of its optical isomers.

[0009] In another more specific embodiment of this invention, the nicotine receptor partial agonist is selected from:

- 9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
- 9-chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
- 9-fluoro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
- 9-ethyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
- 9-methyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
- 9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
- 9-vinyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
- 9-bromo-3-methyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;

- 3-benzyl-9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
- 3-benzyl-9-chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;
- 9-acetyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-iodo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-cyano-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-ethynyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-(2-propenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-(2-propyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-carbomethoxy-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-carboxyaldehyde-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-(2,6-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-(2-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-(4-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-(3-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-(3,5-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-(2,4-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 9-(2,5-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;
- 6-methyl-5-oxo-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;
- 5-oxo-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;
- 6-oxo-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;
- 4,5-difluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
- 5-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene-4-carbonitrile;
- 4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
- 5-ethynyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene-4-carbonitrile;
- 6-methyl-5-thia-5-dioxa-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;
- 10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
- 4-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
- 4-methyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
- 4-trifluoromethyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
- 4-nitro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
- 7-methyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
- 6-methyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
- 6,7-dimethyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
- 6-methyl-7-phenyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,5,8-tetraene;
- 6,7-dimethyl-5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
- 5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
- 14-methyl-5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;
- 5-oxa-7,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,6,8-tetraene;
- 6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,6,8-tetraene;
- 4-chloro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
- 10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-yl cyanide;
- 1-(10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-yl)-1-ethanone;
- 10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-4-ol;
- 7-methyl-5-oxa-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2,4(8),6,9-tetraene;
- 4,5-dichloro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;
- 11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-5-carbonitrile;
- 1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-yl]-1-ethanone;
- 1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-5-yl]-1-propanone;
- 4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-5-carbonitrile;
- 5-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-4-carbonitrile;
- 6-methyl-7-thia-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
- 6-methyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
- 6,7-dimethyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
- 5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
- 5,6-dimethyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;
- 5-methyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;
- 6-(trifluoromethyl)-7-thia-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;
- 5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]heptadeca-2(7),3,5-triene;

ca-2(11),3,5,7,9-pentaene;  
 7-methyl-5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]  
 heptadeca-2(11),3,5,7,9-pentaene;  
 6-methyl-5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]  
 heptadeca-2(11),3,5,7,9-pentaene;  
 6,7-dimethyl-5,8,15-triazatetracyclo[11.3.1.0<sup>2,11</sup>.  
 0<sup>4,9</sup>]heptadeca-2(11),3,5,7,9-pentaene;  
 7-oxa-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]hexa-  
 deca-2(10),3,5,8-tetraene;  
 6-methyl-7-oxa-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.  
 0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;  
 5-methyl-7-oxa-6,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.  
 0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;  
 6-methyl-5-oxa-7,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.  
 0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;  
 7-methyl-5-oxa-6,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.  
 0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;  
 4,5-difluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),  
 3,5-triene;  
 4-chloro-5-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-  
 2(7),3,5-triene;  
 5-chloro-4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-  
 2(7),3,5-triene;  
 4-(1-ethynyl)-5-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]tri-  
 deca-2(7),3,5-triene;  
 5-(1-ethynyl)-4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]tri-  
 deca-2(7),3,5-triene;  
 5,6-difluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-  
 2,4,6-triene;  
 6-trifluoromethyl-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-  
 2,4,6-triene;  
 6-methoxy-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),  
 3,5-triene;  
 11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-  
 6-ol;  
 6-fluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),  
 3,5-triene;  
 11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-  
 5-ol;  
 4-nitro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),  
 3,5-triene;  
 5-nitro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),  
 3,5-triene;  
 5-fluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),  
 3,5-triene; and  
 6-hydroxy-5-methoxy-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]tri-  
 deca-2(7),3,5-triene and

their pharmaceutically acceptable salts and their  
 optical isomers.

**[0010]** Preferably, the nicotine receptor partial agonist  
 is selected from

9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyri-  
 do[1,2-a][1,5]diazocin-8-one;  
 9-chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyri-  
 do[1,2-a][1,5]diazocin-8-one;  
 9-fluoro-1,2,3,4,5,6-hexahydro-1,5-methano-pyri-

do[1,2-a][1,5]diazocin-8-one;  
 9-acetyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyri-  
 do[1,2-a][1,5]diazocin-8-one;  
 9-iodo-1,2,3,4,5,6-hexahydro-1,5-methano-pyri-  
 do[1,2-a][1,5]diazocin-8-one;  
 9-cyano-1,2,3,4,5,6-hexahydro-1,5-methano-pyri-  
 do[1,2-a][1,5]diazocin-8-one;  
 9-carbomethoxy-1,2,3,4,5,6-hexahydro-1,5-meth-  
 ano-pyrido[1,2-a][1,5]diazocin-8-one;  
 9-carboxyaldehyde-1,2,3,4,5,6-hexahydro-  
 1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 9-(2,6-difluorophenyl)-1,2,3,4,5,6-hexahydro-  
 1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyri-  
 do[1,2-a][1,5]diazocin-8-one;  
 9-(2-fluorophenyl)-1,2,3,4,5,6-hexahydro-  
 1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 6-methyl-5-thia-5-dioxa-6,13-diazatetracyclo  
 [9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;  
 4-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),  
 3,5-triene;  
 4-trifluoromethyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]do-  
 deca-2(7),3,5-triene;  
 4-nitro-10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),  
 3,5-triene;  
 6-methyl-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]  
 pentadeca-2(10),3,5,8-tetraene;  
 6,7-dimethyl-5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.  
 0<sup>4,9</sup>]hexadeca-2(11),3,5,7,9-pentaene;  
 5,8,14-triazatetracyclo[10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>]hexadeca-  
 2(11),3,5,7,9-pentaene;  
 5-oxa-7,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]penta-  
 deca-2(10),3,6,8-tetraene;  
 6-methyl-5-oxa-7,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.  
 0<sup>4,8</sup>]pentadeca-2(10),3,6,8-tetraene;  
 10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-  
 4-yl cyanide;  
 1-(10-azatricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-trien-  
 4-yl)-1-ethanone;  
 11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-triene-  
 5-carbonitrile;  
 1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-  
 5-yl]-1-ethanone;  
 1-[11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-  
 5-yl]-1-propanone;  
 4-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),  
 3,5-triene-5-carbonitrile;  
 5-fluoro-11-azatricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),  
 3,5-triene-4-carbonitrile;  
 6-methyl-7-thia-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.  
 0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;  
 6-methyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]  
 hexadeca-2(10),3,5,8-tetraene;  
 6,7-dimethyl-5,7,14-triazatetracyclo[10.3.1.0<sup>2,10</sup>.  
 0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;  
 6-methyl-7-oxa-5,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.  
 0<sup>4,8</sup>]hexadeca-2(10),3,5,8-tetraene;  
 6-methyl-5-oxa-7,14-diazatetracyclo[10.3.1.0<sup>2,10</sup>.

0<sup>4,8</sup>]hexadeca-2(10),3,6,8-tetraene;  
 5,6-difluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-  
 2,4,6-triene;  
 6-trifluoromethyl-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-  
 2,4,6-triene;  
 6-methoxy-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),  
 3,5-triene;  
 6-fluoro-11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),  
 3,5-triene; and  
 11-aza-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2(7),3,5-trien-  
 5-ol and

their pharmaceutically acceptable salts and their optical isomers.

**[0011]** The invention also provides a method of treating a mammal having a condition which presents with tobacco or nicotine addiction, nicotine withdrawal symptoms, alcohol dependence or cocaine or other substance addiction. The mammal is administered a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof, and an antidepressant or anxiolytic agent or a pharmaceutically acceptable salt thereof. The nicotine receptor partial agonist and the anti-depressant or anxiolytic agent are present in amounts that render the composition effective in the treatment of tobacco or nicotine addiction, nicotine withdrawal symptoms, alcohol dependence or cocaine or other substance addiction. In a more specific embodiment of the invention, the anti-depressant is selected from a tricyclic anti-depressant, a serotonin reuptake inhibitor anti-depressant, (SRI), an atypical anti-depressant, and a monoamine oxidase inhibitor. In another more specific embodiment of this invention anxiolytic agent is selected from a benzodiazepine or a non-benzodiazepine anxiolytic. In another more specific embodiment of this invention, the anxiolytic agent is a benzodiazepine or a non-benzodiazepine anxiolytic. In a more specific embodiment of the invention, the anxiolytic agent is selected from diazepam, alprazolam, chlordiazepoxide, buspirone, hydroxyzine and doxepin or a pharmaceutically acceptable salt thereof. A preferable anxiolytic is doxepin or a pharmaceutically acceptable salt or optical isomers thereof.

**[0012]** In another more specific embodiment of this invention the nicotine receptor partial agonist is selected from

9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 9-chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 9-fluoro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 9-ethyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 9-methyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyri-

do[1,2-a][1,5]diazocin-8-one;  
 9-vinyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 9-bromo-3-methyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 3-benzyl-9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 3-benzyl-9-chloro-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one;  
 9-acetyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-iodo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-cyano-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-ethynyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-(2-propenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-(2-propyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-carbomethoxy-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-carboxyaldehyde-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-(2,6-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-phenyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-(2-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-(4-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-(3-fluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-(3,5-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-(2,4-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 9-(2,5-difluorophenyl)-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one;  
 6-methyl-5-oxo-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;  
 5-oxo-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;  
 6-oxo-5,7,13-triazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;  
 4,5-difluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;  
 5-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene-4-carbonitrile;  
 4-ethynyl-5-fluoro-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;  
 5-ethynyl-10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene-4-carbonitrile;  
 6-methyl-5-thia-5-dioxa-6,13-diazatetracyclo[9.3.1.0<sup>2,10</sup>.0<sup>4,8</sup>]pentadeca-2(10),3,8-triene;  
 10-aza-tricyclo[6.3.1.0<sup>2,7</sup>]dodeca-2(7),3,5-triene;

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.